Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Looks To Pediatric Oncology Subcommittee For Trial Advice, But Gets Little Clarity

You may also be interested in...



Breakthrough Status Arrives Late In Development Of Yervoy+Opdivo, Enfortumab Vedotin And Pedmark

US FDA's latest BTD awards go to Seattle Genetics and Astellas' antibody-drug conjugate for immunotherapy-experienced urothelial cancer, Fennec's supportive care product to reduce cisplatin ototoxicity in pediatric cancer patients, and Bristol's double immunotherapy combo in MSI-H colorectal cancer.

FDA Pediatric Oncology Advisors Seek Meaningful Trial Plans For Mutually Beneficial Review

As the message that pediatric trials may be necessary or required has apparently gotten across to industry, ODAC’s Pediatric Subcommittee is ready to advise developers on trials that might help improve the way pediatric cancer drugs are developed. Nominations are being accepted for its December meeting.

Votrient Combination Therapy Still An Option In Pediatrics, Subcommittee Tells GSK

The company reported difficulties combining the drug with other chemotherapies in adults, but FDA's pediatric oncology subcommittee says that may not be the case in children.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS053912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel